QUOTE AND NEWS
SeekingAlpha  Aug 1  Comment 
SurModics Inc. (NASDAQ:SRDX) Q3 2014 Earnings Conference Call July 31, 2014 3:00 PM ET Executives Andy LaFrence – Vice President of Finance and Chief Financial Officer Gary Maharaj – President and Chief Executive Officer ...
Benzinga  Jul 28  Comment 
Cerus (NASDAQ: CERS) shares reached a new 52-week low of $3.58. Cerus is expected to release Q2 results on July 31, 2014. Perion Network (NASDAQ: PERI) shares touched a new 52-week low of $8.89. Perion Network shares have dropped 22.76% over the...
SeekingAlpha  May 23  Comment 
By Zacks Investment Research: SurModics (SRDX) is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation and medical diagnostics. SurModics partners...
SeekingAlpha  May 2  Comment 
SurModics, Inc. (SRDX) F2Q2014 Earnings Conference Call May 1, 2014 5:00 PM ET Executives Andrew D. C. LaFrence – Vice President -Finance and Chief Financial Officer Gary R. Maharaj – President and Chief Executive Officer ...
Benzinga  Apr 4  Comment 
Analysts at Northland Securities initiated coverage on shares of Cisco Systems (NASDAQ: CSCO) with an “outperform” rating. The target price for Cisco Systems is set to $28. Cisco's shares closed at $23.09 yesterday. Cowen & Company...
SeekingAlpha  Feb 5  Comment 
SurModics, Inc. (SRDX) Annual Shareholder Meeting Call February 4, 2014 17:00 ET Executives Bob Buhrmaster - Chairman Bryan Phillips - General Counsel and Corporate Secretary Gary Maharaj - President and Chief Executive Officer ...
SeekingAlpha  Jan 31  Comment 
SurModics, Inc. (SRDX) F1Q 2014 Results Earnings Call January 30, 2014 5:00 PM ET Executives Andy LaFrence - Vice President, Finance and CFO Gary Maharaj - President and CEO Analysts Ross Taylor - CL King Beth Lilly -...
SeekingAlpha  Jan 30  Comment 
Complete Story »
StreetInsider.com  Jan 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/SurModics%2C+Inc.+%28SRDX%29+Reports+In-Line+Q4+EPS%3B+Boosts+Outlook/9108068.html for the full story.
Forbes  Dec 10  Comment 
Fourth quarter fiscal year 2013 results were mixed, with weaker forward guidance.




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

SurModics is a provider of surface modification and drug delivery technologies to the healthcare industry. The company operates in three operating segments: Drug Delivery, Hydrophilic Technology and Other, and In Vitro. The Drug Delivery segment contains the drug delivery business unit, which is responsible for technologies dedicated to site-specific delivery of drugs, and the Ophthalmology division, which is dedicated to the advancement of treatments for eye diseases, such as age-related macular degeneration (AMD) and diabetic macular edema (DME). The acquisition of Brookwood Pharmaceuticals in August 2007 added proprietary polymer platform technologies to this segment in addition to both systemic and site specific drug release technologies.

The Hydrophilic and Other operating segment consists of Hydrophilic Technologies business unit, which focuses on enhancing medical devices with advanced lubricious coatings that facilitate their placement and maneuverability in the body Regenerative Technologies business unit, which develops platforms intended to augment or replace tissue/organ function (e.g., cell encapsulation applications), or to modify medical devices to facilitate tissue/organ recovery through natural repair mechanisms (e.g., biocompatible or prohealing coatings) and Orthopedics business unit, which is committed to innovative solutions for orthopedics patients using proven SurModics technologies, and creating new technology solutions to existing patient care gaps in the orthopedics field. The In Vitro operating segment contains the in vitro technologies (formerly Diagnostics and Drug Discovery) business unit, which includes genomics slide technologies, stabilization and antigen products for immunoassay diagnostic tests, in vitro diagnostic format technology and synthetic cell culture products. The product portfolio of this segment was broadened with the acquisition of BioFX Laboratories in August 2007.

Revenue in each of the three operating segments is derived from three primary sources: royalties and license fees from licensing patented surface modification and drug delivery technologies and in vitro diagnostic formats to customers the sale of reagent chemicals to licensees of its technologies, stabilization products to the diagnostics industry and coated glass slides to the genomics market research and development fees generated on customer projects.

SurModics serves medical device, pharmaceutical, and life science companies, as well as development stage companies. The company's customer base and market presence were greatly expanded with the acquisitions of Brookwood Pharmaceuticals and BioFX Laboratories in August 2007. SurModics markets its technologies and products worldwide. The company was founded in 1979. It was formerly known as BSI Corporation and changed its name to SurModics, Inc. in 1997. The company went public in 1998. SurModics is headquartered in Eden Prairie, Minnesota.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki